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The GYN GEC-ESTRO working group issued three parts of recommendations and highlighted the pivotal
role of MRI for the successful implementation of 3D image-based cervical cancer brachytherapy (BT). The
main advantage of MRI as an imaging modality is its superior soft tissue depiction quality. To exploit the
full potential of MRI for the better ability of the radiation oncologist to make the appropriate choice for
the BT application technique and to accurately deﬁne the target volumes and the organs at risk, certain
MR imaging criteria have to be fulﬁlled. Technical requirements, patient preparation, as well as image
acquisition protocols have to be tailored to the needs of 3D image-based BT. The present recommenda-
tion is focused on the general principles of MR imaging for 3D image-based BT.
Methods and parameters have been developed and progressively validated from clinical experience from
different institutions (IGR, Universities of Vienna, Leuven, Aarhus and Ljubljana) and successfully applied
during expert meetings, contouring workshops, as well as within clinical and interobserver studies.
It is useful to perform pelvic MRI scanning prior to radiotherapy (‘‘Pre-RT-MRI examination’’) and at the
time of BT (‘‘BT MRI examination’’) with one MR imager. Both low and high-ﬁeld imagers, as well as both
open and close magnet conﬁgurations conform to the requirements of 3D image-based cervical cancer
BT.Multiplanar (transversal, sagittal, coronal and oblique image orientation) T2-weighted images obtained
with pelvic surface coils are considered as the golden standard for visualisation of the tumour and the crit-
ical organs. The use of complementaryMRI sequences (e.g. contrast-enhanced T1-weighted or 3D isotropic
MRI sequences) is optional. Patient preparation has to be adapted to the needs of BT intervention and MR
imaging. It is recommended to visualise and interpret theMR images on dedicatedDICOM-viewerworksta-
tions, which should also assist the contouring procedure. Choice of imaging parameters and BT equipment
is made after taking into account aspects of interaction between imaging and applicator reconstruction, as
well as those between imaging, geometry and dose calculation.
In a prospective clinical context, to implement 3D image-based cervical cancer brachytherapy and to take
advantage of its full potential, it is essential to successfully meet the MR imaging criteria described in the
present recommendations of the GYN GEC-ESTRO working group.
 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Radiotherapy and Oncology 103 (2012) 113–122Radiotherapy (RT) and in particular brachytherapy (BT) have
been major treatment modalities for cervical cancer for over
100 years with BT treatment planning mainly based on radio-
graphs and point dosimetry. In the late 90’s MR image guidance
was introduced into BT treatment planning. The Gynaecological
(GYN) GEC-ESTRO working group then issued recommendationsadiotherapy, Comprehensive
ospital of Vienna, Währinger
ichard.poetter@meduniwien.
er CC BY-NC-ND license.for MRI based adaptive target concepts, 3D based adaptive dose
volume parameters for target and organs at risk including aspects
of 3D image-based MRI anatomy, radiation physics and radiobiol-
ogy, and recently also for applicator reconstruction [1–3].
According to the dramatic changes in regard to tumour, target
and normal tissue topography during external beam radiochemo-
therapy repetitive imaging studies are necessary to assess the
individual situation at a given time point during treatment [4–11].
In the GYN GEC-ESTRO recommendations the suggestion has
been to perform MR imaging prior to treatment (‘‘ Pre-RT MRI
examination’’) and at the time of BT (‘‘BT MRI examination’’) with
114 GYN GEC ESTRO MR imaging recommendations for cervical cancer BTthe applicator in place. The ‘‘Pre-RT MRI examination’’ as addressed
here is related to the needs of the following RT and should be
performed as much as possible along the lines of the following
repetitive imaging studies, in particular at the time of BT.
The basic imaging concepts of diagnostic radiology therefore can
be applied for the ‘‘Pre-RT MRI examination’’ with some adaptations
for comparability to the subsequent ‘‘BTMRI examination’’ which has
to be performed according to the needs of BT treatment planning.
The basic principles are elaboratedwithin the following recommen-
dations. Taking into account these principles appropriate institu-
tional MR imaging protocols have to be set up in close cooperation
between radiation oncologists and diagnostic radiologists.
In order to achieve this aim of combining diagnostic and thera-
peutic radiology needs within the GYN GEC-ESTRO working group
and network at least one diagnostic radiologist (PP) with subspeci-
alisation in gynaecologic imaging has participated continuously in
the expert meetings, the various workshops and in the ESTRO 3D
Gyn Teaching Course. This close cooperation has been the backbone
of these imaging recommendationswhich deal with all the different
issues of interest in the context of MRI based adaptive cervix cancer
BT. Dedicated imaging protocols were developed, implemented and
evaluated by various members of the working group and the net-
work in their respective clinical context and in small scale studies
including interobserver studies using various MRI scanners (0.2–
1.5 Tesla (T)) from different vendors. The feasibility of these proto-
cols could be shown [12–24]. The image studies as being proposed
within the following recommendations enable under the suggested
conditions straightforward image reading and an appropriate deﬁ-
nition of target and organs at risk (OAR) and adaptive treatment
planning according to the terms and concepts as elaborated in the
three preceding recommendations. In addition there is agreement
among the clinical and imaging experts that the adaptive treatment
planning process has to be based also on repetitive clinical gynaeco-
logical examination with documentation on repetitive 3D clinical
drawings (‘‘clinical imaging’’). [1,3].
The following recommendations from the GYN GEC-ESTRO
working group/network, on imaging for 3D image-based adaptive
treatment planning in cervical cancer BT, are based on the expert
experience from clinical practice in a limited number of centres
and on evidence from a limited number of clinical imaging studies
[12–15,18–22,24].Demands on MR imaging for cervical cancer BT
For the individual patient the choice of appropriate BT applica-
tion technique, as well as precision of target and organ contouring
depend, even if only to a certain degree (see also clinical examina-
tion in [1,3]), on parameters obtained from MRI. To meet these de-
mands for 3D image-based cervical cancer BT, MRI must provide:
– sufﬁcient information about tumour extent, tumour growth pattern
and topography of patho-anatomical structures in three dimensions
(3D) at the time of diagnosis (‘‘Pre-RT MRI examination’’),
– sufﬁcient information about tumour/target extent, tumour/tar-
get growth pattern and topography of patho-anatomical struc-
tures in three dimensions (3D) at the time of BT with the
applicators in place (‘‘BT MRI examination’’),
– comprehensive information about quantitative and qualitative
tumour regression during the entire course of RT in four dimen-
sions (4D-including changes in time) (‘‘Pre-RT MRI examina-
tion’’/‘‘BT MRI examination’’ comparison).
Reproducible observation of this imaging information through-
out RT treatment course can only be guaranteed if dedicated imag-
ing protocols are applied for both ‘‘Pre-RT MRI examination’’ and ‘‘BTMRI examination’’. Repetitive imaging with reproducible image
quality and reproducible image contrast is only provided if these
protocols meet certain criteria regarding technical requirements
for the MRI unit, patient preparation, image acquisition and com-
patibility of BT equipment with MRI, taking also into consideration
the important aspects of the interaction between imaging and
applicator reconstruction, as well as those of the interaction be-
tween imaging, geometry and dose calculation.Technical requirements
Magnet ﬁeld strength
Both low (0.1–0.5 T) and high 1.0–1.5 T ﬁeld imagers conform
to the requirements of ‘‘Pre-RT MRI examination’’ and ‘‘BT MRI
examination’’ [25,26]. Clinical experience with higher magnet ﬁeld
strength (3 T or higher) in diagnostic radiology is growing, but re-
ports with its use for 3D image-based cervical cancer BT are lim-
ited, mainly because of issues of image distortion, artefacts and
potential heating effects from BT applicators during MRI scanning
[27]. Data about the clinical use of lowest magnet ﬁeld strength
MRI scanners (0.02 T) for cervical cancer patients are also limited
[28,29]. However, for the radiation oncologist, to avoid differences
in contrast and image quality between ‘‘Pre-RT MRI examination’’
and ‘‘BT MRI examination’’ it is useful to obtain both scans with
the same imager.Magnet conﬁguration
Both open and closed magnet conﬁgurations can be used for
‘‘Pre-RT MRI examination’’ and ‘‘BT MRI examination’’. Open MRI
scanners offer improved patient accessibility, but to date, ‘‘real-
time’’ image-guidance during the BT intervention is possible nei-
ther with open nor closed scanners. However, direct visualisation
of the applicator during insertion in ‘‘real-time’’ may be enabled
by future developments in the ﬁeld.Coils
Coils are used to increase the signal-to-noise ratio (SNR) of the
scanned region [30–34]. A surface pelvic coil wrapped around the
pelvis is considered as standard for diagnostic pelvic MR imaging
(staging and follow-up) and is also recommended for ‘‘Pre-RT MRI
examination’’ and ‘‘BT MRI examination’’. MR imaging with intracav-
itary, (i.e. intrarectal or intravaginal) coils improve visualisation of
small intracervical tumours, but are not routinely used. The use of
such intracavitary coils for cervical cancer BT is neither described
nor is it recommended. Changes in organ shape and topography
after MR image acquisition and coil removal would be associated
with major dosimetric uncertainties during treatment planning.
In addition, MRI scans performed with intrarectal coils would not
cover the entire region of interest [30,32,34].Patient preparation – contrast application
To conform to the requirements of BT intervention and MR
imaging, bowel preparation (e.g. per oral application of Polyethy-
lenglycol 3350 with electrolytes) started 2 days prior to the inter-
vention, can be performed.
To reduce bowel motion, intravenous or intramuscular anti-
spasmodic drug administration should be considered (e.g. N-
Butylscopolan or Glucagon chlorhydrate) (Fig. 1a and b). MR image
quality can be further improved by reducing the anterior abdomi-
nal wall motion amplitude with a large elastic band and by reduc-
ing the signal from the air/subcutaneous fat interface with an
Fig. 1. Effect of antispasmodic drug administration on MR image quality: small bowel peristalsis causes movement artefacts in MRI (a). A spasmolytic agent (e.g. N-
Butylscopolan or Glucagon chlorhydrate) is therefore commonly administered intravenously to inhibit bowel motion shortly before performing pelvic MRI (b). In (a) the
sagittal T2w MR image is blurred due to small bowel motion and due to uterine contraction. In (b) the sagittal T2w MR image of the same patient appears with signiﬁcant
improvement of image quality since it is obtained after injection of Glucagon chlorhydrate.
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fat interface alters image quality in the phase-encoding direction.
Clinical examination is considered to be the golden standard for
evaluation of vaginal invasion, due to direct examination of the or-
gan, in particular in combination with vaginal impression [35,36].
Intracavitary contrast-enhanced imaging with intravaginal appli-
cation of intermediate-to-high signal intensity contrast-media for
‘‘Pre-RT MRI examination’’ unfolds the vaginal fornices thus reveal-Fig. 2. MR image plane orientation and coverage of T2w pelvic scanning for assessment
with bulky IIB disease: (a–c) demonstrate the ‘‘Pre-RT MRI examination’’ with para-ax
orientation remained the same for ‘‘4th week EBRT MRI examination’’ (d–f) and for ‘‘BT M
tumour response during EBRT in this particular patient. Such repetitive MRI is not necess
however clinical repetitive examination is mandatory with documentation on 3D clinical
coronal and sagittal scout views, respectively. Para-axial slices are orientated perpend
orientated parallel to the long axis of the cervical canal. The coverage which should be ob
the bulky IIB tumour which is mainly located in the anterior part of the cervix and invad
the remnants are remaining mainly located in the anterior part of the cervix and both par
insertion additional shrinkage of the tumour is observed and residual gross tumour, as w
part of the right parametria.ing signs of invasion and exophytic tumour growth [37,38] (Fig. 2).
Van Hoe et al. used a mixture of barium, water, and maltodextrin/
calcium lactate for this purpose [38]. Ultrasound gel is a widely
available alternative. With the patient in supine position on the
MRI table, 30–50 cc of the gel are injected with a sterile syringe
into the vagina until reﬂux is obtained [15,38].
Urine is displayed with high-signal intensity on T2-weighted
images and with sufﬁcient contrast to the low-intensity muscularof dynamic tumour response during radiochemotherapy of a cervix cancer patient
ial, sagittal and para-coronal slice orientation, respectively. The MR image plane
RI examination’’ (g–i). ‘‘4th week EBRT MRI examination’’, was performed to illustrate
arily required for the performance of MR image guided cervix cancer brachytherapy,
drawing. Para-axial, sagittal and para-coronal slice orientation is selected on sagittal,
icular to the long axis of the cervical canal. Sagittal and para-coronal slices are
tained is described in detail in the text. The ‘‘Pre-RT MRI examination’’ demonstrates
es both parametria (right > left). During EBRT the tumour is shrinking signiﬁcantly,
ametria are still invaded. On ‘‘BT MRI examination’’ which is obtained after applicator
ell as grey zones are restricted to the right anterior parts of the cervix and the inner
116 GYN GEC ESTRO MR imaging recommendations for cervical cancer BTbladder. Therefore, retrograde intravesical contrast application is
not required.
It is recommended to apply dedicated bladder ﬁlling protocols
in order to achieve reproducible bladder ﬁlling during image acqui-
sition and BT delivery.
A foley catheter is inserted and the catheter-balloon is ﬁlled
with 7 cm3 of ﬂuid which is either diluted gadolinium contrast
agent (e.g. dilution 1:1) for 0.2 T MR imaging or it is normal saline
solution for 1.5 T MR imaging. When using HDR, a speciﬁc bladder
ﬁlling can be used by opening the catheter to empty the bladder
and then instilling, prior to MRI scanning, a certain volume (e.g.
50 ml) of saline solution. The urinary catheter is then left open
throughout the entire treatment planning procedure and the
50 ml saline solution is then again instilled prior to the BT delivery
process. When using PDR, the catheter has to be left open during
treatment, and therefore the bladder should be emptied prior to
MR scanning.
The ‘‘BT MRI examination’’ has to be performed with the BT
applicator in place. On T2-weighted sequences, commercially
available MRI-compatible applicators and MRI-compatible intersti-
tial titanium or plastic needles are depicted with low-signal inten-
sity and with sufﬁcient contrast to the adjacent patho-anatomical
structures, which are displayed with intermediate to high signal
intensity [39,40].
For the ﬁxation of the applicator and to displace the rectum and
the bladder from the intravaginal parts of the applicator, it is rec-
ommended to use vaginal packing with a cotton gauze. The pack-
ing can be impregnated with diluted gadolinium contrast agent
(e.g. dilution 1:10 in 0.2 T) or can be left dry (e.g. in 1.5 T). In this
way, the packing will be depicted with low signal on T2-weighted
sequences (Fig. 2). The latter guarantees improved discrimination
quality for the depiction of the lower parts of the cervix/tumour
which are displayed with high to intermediate signal on T2-
weighted sequences [15]. A similar effect is observed for the border
between the vagina and packing if there is no signal in the vagina
(Fig. 2).
The use of rectal in vivo diode dosimeters (e.g. PTW AM6 diode,
diameter 10 mm, PTW Freiburg, Germany) is optional. Such diodesTable 1
Image acquisition protocols for pre-RT MRI scan and BT MRI scan. This table summarises t
each of the different MRI sequences.
Protocol Number Mandatory (M)/
optional (O)
Sequence Plane orientation
Pre-RT
MRI
scan
1 M T2 FSE Para-axial (accor
cervix uteri)
2 M T2 FSE Sagittal
3 M T2 FSE Para-coronal (acc
to cervix uteri)
4 M T2 FSE Axial
5 O T1 FSE or 3D GRE
without contrasta
Axial
6 O T1 FSE with contrasta Sagittal
7 O T1 FSE or 3D GRE with
contrasta
Axial (isotropic 3
BT MRI
scan
8 M T2 FSE Para-axial (accor
cervix uteri)
9 M T2 FSE Para-sagittal (acc
to cervix uteri)
10 M T2 FSE Para-coronal (acc
to cervix uteri)
11 O T2 FSE Axial
12 O 3D T2 FSE isotropic Coronal or axial
reconstructions
13 O T1 FSE, FLASH, T1 GRE
3D
As appropriate
a When contrast series are applied (6 and/or 7): use same T1 sequence for pre-contraare inserted through a plastic probe into the rectum to approxi-
mately 15 cm from the anus. The diode dosimeters contain metal
and have to be removed during MR image acquisition. The plastic
probe, which is remaining in the patient, is also depicted with
low signal-intensity on T2-weighted MR images.Image acquisition
Imaging parameters: technique (e.g. spin echo (SE), fast spin
echo (FSE), turbo spin echo (TSE)), repetition times (TR), echo times
(TE), ﬁeld of view (FOV) and matrix of data collection are summa-
rised in Tables 1 and 2.Sequences
OAR (bladder, vagina, rectum and sigmoid colon) and the rele-
vant patho-anatomical structures (uterine cervix and corpus, vagi-
na, parametria, tumour, ‘‘grey zones’’) are appropriately visualised
on T2-weighted MR images, without contrast media injection
[15,41–43]. Therefore, T2-weighted sequences are considered to
be the basic sequences, which should always be performed. SE
and FSE T2-weighted sequences are of equal value, although the
latter reduce image acquisition time.
Acquisition of T1-weighted spin-echo images is not mandatory,
but can be performed in addition for pelvic nodal status evaluation.
Contrast-enhanced T1-weighted images may help to deﬁne patho-
logical conditions such as ﬁstulas, tumour necrosis and pelvic
abscesses.
The most commonly used post contrast-enhanced T1-weighted
sequences are 2D SE or 3D Gradient-echo (GRE) sequences, which
can be obtained with or without fat-saturation. The choice of
whether using fat-saturation or not, depends on scanner type
and individual preferences.
Contrast-enhanced images overestimate tumour extension due
to enhancement of peri-tumoural oedema [35,44]. Therefore, dy-
namic-acquisition and post contrast-enhanced T1-weighted MRI
sequences do not replace T2-weighted sequences, especially with
regard to estimation of parametrial tumour extension.he important information regarding sequence, plane orientation, coverage/borders for
Coverage/borders
ding to Above uterine corpus – inferior border of symphysis pubis/entire
vagina if distal vaginal involvement
Pelvic side wall (obturator muscle)
ording Uterine corpus – cervix – vagina – tumour
Discus L4–L5 – inferior border of symphysis pubis/entire vagina and
inguinal regions if distal vaginal involvement
Discus L4–L5 – inferior border of symphysis pubis/entire vagina and
inguinal regions if distal vaginal involvement
Pelvic side wall (obturator muscle)
D GRE) Uterine corpus – cervix – vagina – tumour
ding to Above uterine corpus – 3 cm below lower surface of vaginal applicator/
entire vagina if distal vaginal involvement
ording Pelvic side wall (obturator muscle)
ording Uterine corpus – cervix – vagina – tumour
Above uterine corpus – 3 cm below lower surface of vaginal applicator/
entire vagina if distal vaginal involvement
with Large coverage inherent in this sequence
At least entire applicator
st and lymph node evaluation.
Table 2
Image acquisition protocols for pre-RT MRI scan and BT MRI scan. This table summarises the important information regarding sequence parameters for each of the different MRI
sequences. The numbering of sequences is the same as in Table 1.
Protocol Sequence parameters
Number Fatsat TR (ms)a TE (ms)b ETLc FOV (cm2)d M(f)e M(p)e Nexf SWg NPWh
Pre-RT MRI scan 1 No 2000–5000 90–120 4–20 35  20 512 256 2 3–4 Yes
2 No 2000–5000 90–120 4–20 35  40 512 256 2 5 Yes
3 No 2000–5000 90–120 4–20 35  20 512 256 2 3–4 Yes
4 No 2000–5000 90–120 4–20 35  40 512 256 2 5 Yes
5 TSE Optional 500–700 10–20 NA 35  20 512 256 2 5–7 Yes
3D GREi Optional 5–10 2–5 i 37  30 i i i 1–4 i
6 TSE Optional 500–700 10–20 NA 35  20 256 256 2 3–5 Yes
7 TSE Optional 500–700 10–20 NA 35  20 256 256 2 3–5 Yes
3D GREi Optional 5–10 2–5 i 37  30 i i i 1–4 i
BT MRI scan 8 No 2000–5000 90–120 4–20 35  20 512 256 2 3–5 Yes
9 No 2000–5000 90–120 4–20 35  40 512 256 2 3–5 Yes
10 No 2000–5000 90–120 4–20 35  20 512 256 2 3–5 Yes
11 No 2000–5000 90–120 4–20 35  40 512 256 2 3–5 Yes
12 No See Refs. [22,48–56] for sequence parameters
13 No
a TR = time of repetition.
b E = time of echo.
c ETL = echo train length or turbo factor.
d FOV = minimum ﬁeld of view.
e M = matrix: (f) = frequency, (p) = phase.
f Nex = number of excitations.
g SW = slice width.
h NPW = no phase wrap.
i Exact parameters depending on vendor, gradient performance, and parallel imaging abilities, GRE = gradient echo.
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Minimum requirement for ‘‘Pre-RT MRI examination’’ are T2-
weighted sequences in para-axial (orthogonal to the uterine axis),
para-sagittal and para-coronal (parallel to the uterine axis) orien-
tation (Fig. 2). T1-weighted sequences in axial orientation, as well
as dynamic contrast-enhanced T1-weighted sequences in para-ax-
ial and para-sagittal orientation after bolus injection of contrast
can be performed in addition.
‘‘BT MRI examination’’ images are acquired after applicator
placement (Fig. 2). Minimum requirements for ‘‘BT MRI examina-
tion’’ are T2-weighted sequences in para-axial, para-sagittal and
para-coronal orientation, which are orientated orthogonal and par-
allel to the applicator axis [15,21,45] (Fig. 2). Axial images, orien-
tated orthogonal to the MRI table, have to be acquired in
addition, if this is required by the treatment planning system
[21,23].
Para-axial images (Fig. 2) are obtained from the level above the
uterine fundus to inferior border of the symphysis pubis below any
vaginal tumour extension. In case of invasion of the distal vagina,
axial ‘‘Pre-RT MRI examination’’ images should also cover the vulva
and the groins and the ‘‘BT MRI examination’’ should include the va-
gina. The superior border of axial ‘‘Pre-RT MRI examination’’ images
is set at the level of the intervertebral disc L4–L5. Sagittal images
are obtained between internal obturator muscles (Fig. 2). Para-
coronal (Fig. 2) and para-axial images (Fig. 2) include the tumour,
entire cervix, corpus uteri, parametria and vagina. Image coverage
between ‘‘Pre-RT MRI examination’’ and ‘‘BT MRI examination’’
should not differ. Sagittal imaging facilitates detection of organ
invasion (bladder, rectum, vagina, small bowel and sigmoid colon)
[46]. Para-coronal MR images (Fig. 2) facilitate evaluation of para-
metrial invasion [47] and may exclude partial volume artefacts at
the level of the vaginal fornices.Sequence parameters
Scanning parameters differ principally between MR scanners
and have to be adapted to the speciﬁc device in collaboration with
the diagnostic radiologist. Tables 1 and 2 summarise characteristicscanning parameters. TR, TE and echo train length (ETL) determine
the weighting of the sequence (e.g. T2- or T1-weighted sequences).
ETL determines the repetition of the received echo in fast spin-echo
sequences. The FOV should be adapted to the individual patient in
order to encompass the entire pelvis and to avoid fold-over arte-
facts. FOV usually ranges from 35 to 45 cm, but for para-coronal se-
quences it should range between 20 and 35 cm to enable improved
tumour delineation accuracy into the direction of the parametria.
In order to keep the acquisition time short for routine examina-
tions, the matrix in the phase-encoding direction should not ex-
ceed 256 and should be placed in anterior–posterior direction on
axial MRI sequences. In 3 T scanning, the phase direction can be
placed also in cranio-caudal or left–right direction. The matrix size
in the frequency-encoding direction can range from 256 to 512. On
sagittal and axial T2-weighted MR images, slice thickness can vary,
but should not exceed 5 mm. Interslice gap (ISG) between two
slices can be used to avoid slice interference, but may be omitted
for the para-transverse or transverse ‘‘BT MRI examination’’ in order
to improve accuracy of applicator reconstruction. On para-axial T2-
weighted images, 3 mm slice thickness increases diagnostic accu-
racy for the detection of parametrial invasion [47]. Sufﬁcient SNR
can be mostly achieved with two or more excitations, which also
allows the use of fold over suppression (no phase wrap).3D isotropic fast spin-echo imaging with high sampling
efﬁciency
Conventional 3D T2w TSE MRI is characterised by long scanning
times, which is reﬂected in high sensitivity for motion and suscep-
tibility artefacts. Standard technique of MRI therefore currently
consists of 2D T2w TSE image acquisition in three main orthogonal
planes. Recently, 3D T2w TSE MRI sequence with high sampling
efﬁciency (SPACE) has been introduced for diagnostic imaging of
the pelvis and other anatomical regions [48–56]. Parallel imaging,
high turbofactor and magnetisation restore pulses are applied in
this sequence, along with non slice-selective pulse trains consist-
ing of variable ﬂip angle radiofrequency pulses along the echo
train, as opposed to the constant ﬂip angle refocusing of the
118 GYN GEC ESTRO MR imaging recommendations for cervical cancer BTconventional TSE imaging [53]. The 3D sequence is characterised
by a large ﬁeld of view, enabling coverage of the entire pelvis with-
in one single acquisition, and a sufﬁcient signal-to-noise and con-
trast-to noise ratios. Due to a small isotropic voxel size (e.g.
1  1  1 mm), free reformatting of thin slices in any plane is pos-
sible during image interpretation while partial volume artefacts
are avoided. The ability to reconstruct high-resolution images in
any relevant plane allows tracing of key patho-anatomical features
and the BT applicator without the need for additional scanning. Fu-
sion between 3D isotropic sequences and 2D T2W para-axial is
promising for 3D image-based cervical cancer BT planning, for
the purpose of both contouring [22] and for accurate reconstruc-
tion of the BT applicators [2]. Further studies are needed, however,
to elucidate the role of 3D MRI in ‘‘Pre-RT MRI examination’’ and ‘‘BT
MRI examination’’ by benchmarking it against the gold-standard 2D
approach as the higher and isotropic resolution comes at the price
of different contrast behaviours of the 3D sequence.MRI compatibility of BT equipment
Applicators have to be MRI-compatible in order to avoid image
distortion, heating and mechanical tissue injuries. Non-metallic
(e.g. plastic) and titanium applicators are commercially available,
and the individually produced resin mould applicator is also MRI
compatible. Non-metallic applicators do not interfere with the
magnetic ﬁeld, and they appear as black voids in the images. Tita-
nium applicators are usually validated by the vendors up to ﬁeld
strengths of 1.5 T with regard to heating effects and magnetic dis-
placement. Validation of titanium applicators for 3 T scanners is
typically pending, but initial studies indicate that they can be
safely used with regard to heating and torque [27]. Although tita-
nium applicators are MRI-compatible, they do induce susceptibil-
ity artefacts on both 1.5 T and 3 T – particularly in regions of
considerable material thickness which is typically at the end of
the tandem, needle, ovoid, and ring channels. In particular with
3 T MRI, titanium applicators may compromise the image quality
due to susceptibility artefacts. The titanium artefacts depend on
image sequence and may extend beyond 5–10 mm on 3 T T2-
weighted sequences whereas they may be less than 3–5 mm on
3 T T1-weighted MRI [27]. The position and extent of titanium
artefacts should be assessed by performing both MR and CT imag-
ing of the applicator in a phantom.
Rectal in vivo diode dosimeters contain metal and have to be re-
moved during MR imaging. A sheath can be inserted in order to
facilitate insertion of the dosimeter after imaging.Geometry considerations and dose calculation
The spatial accuracy of MR images is crucial for precise dose
planning in RT [17,57,58]. The impact of spatial distortions will di-
rectly translate into dose calculation uncertainties according to the
BT dose gradient of around 5–10% per mm. Therefore, it has to be
kept in mind that control of the geometric accuracy of the MR
imaging system is mandatory to make this concept meaningful.
However, as opposed to external beam RT, BT dose calculation does
not rely on the external body contour, and it is fortunately only
necessary to address the spatial accuracy in the region of the appli-
cator and relevant anatomy (target and OAR). For a dose precision
of e.g. 5% at point A (2 cm from the intrauterine channel and typical
dose gradient of 6% per mm) the geometrical accuracy of the MR
acquisition needs to be within 1 mm. Such accuracy can be ob-
tained with typical MRI sequences in the region of the BT applica-
tor [59]. Of special concern is the geometrical accuracy in the
immediate vicinity of the tandem, applicator and needles, where
susceptibility artefacts introduce local geometrical distortions.
Susceptibility distortions are ﬁeld dependent, but it has so far beenproven that these distortions are acceptable for magnetic ﬁeld
strengths up to 1.5 T [60] and 3 T [27].
Geometric distortions are sequence dependent and this has to
be taken into account when choosing MRI-sequences. Fortunately
the geometric stability of standard T2-weighted spin-echo and tur-
bo spin-echo sequences is fairly robust to susceptibility artefacts,
while fast imaging techniques like gradient echo techniques and
echo planar imaging (EPI) techniques as used for diffusion
weighted imaging (DWI) are much more prone to induce geomet-
rical instability.
To assure constant quality of MR imaging during time of BT and
to assess the impact of magnetic-ﬁeld sensitive devices or implants
and their repercussions on geometry in ‘‘BT MRI examination’’, cal-
ibration tests done before and during ‘‘BT MRI examination’’ should
be performed with phantoms that allow estimation of the geomet-
ric/spatial accuracy, and a regular schedule should be established
in accordance with local guidelines.
Advanced BT dose calculation takes into account tissue inhomo-
geneities by basing the calculation on CT and electron density
information. However, with high energy sources like 192-Ir, 137-
Cs, 60-Co, the energy dependence on tissue inhomogeneities is
modest, and furthermore, in cervical cancer, the radiation is deliv-
ered far from the surface of the patient. Therefore the dose calcu-
lation accuracy is not compromised when using MR images for
dose planning based on water dose calculation.Imaging and applicator reconstruction
The choice of image sequences should take into account appli-
cator reconstruction. GEC-ESTRO recommendations for applicator
reconstruction have been published and these describe in detail
the complete reconstruction procedure [2]. In the following para-
graph, issues related to MRI and applicator reconstruction will be
described.
The traditional X-ray marker string with small metal markers is
not MRI-compatible and it is more difﬁcult to deﬁne the source
channel on MRI than with CT or X-ray. Special MRI markers like
catheters containing water, CuSo4 solution or glycerine are alter-
natives [12,60,61], or other markers can be used to guide the
reconstruction [62]. Slice thickness is an important parameter
which has direct impact on the precision of reconstruction, and it
is recommended to perform reconstruction in image series ob-
tained with a slice thickness less than or equal to 5 mm. T2-
weighted 3D sequences offer an excellent visualisation of the
applicator and markers inserted into the source channels. 3D imag-
ing also makes it possible to perform reconstruction in the same
image sequence as contouring [22]. Alternative strategies may in-
volve reconstruction in other image sequence (e.g. CT or additional
MRI sequences) which are fused to the T2-weighted images which
contain the contours [14]. This approach is particularly useful in
cases with needles which may be difﬁcult to deﬁne accurately on
T2-weighted images. However, it has to be taken into account that
fusion uncertainties will add on top of reconstruction uncertain-
ties. Miss-registrations can involve considerable reconstruction er-
rors with signiﬁcant impact on dose [63,64].Discussion
The present manuscript is published to supplement in particu-
lar the Recommendations from the Gynaecological (GYN) GEC-ES-
TRO Working Group (I), which emphasised on concepts and terms
on MRI assessment of gross target volume (GTV) and clinical target
volume (CTV) for cervical cancer BT [1]. In the subsequent para-
graphs the GYN GEC-ESTRO recommendations for MR imaging
for 3D image-based cervical cancer BT are discussed based on the
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cal experience and as supported by data from the literature.
MR imaging, when performed with adequate imaging protocols,
meets the demands for 3D image-based BT for cervical cancer
[5,13,18–21,65–68]. It provides essential information about tu-
mour extent, topography and regression, as well as topography
of patho-anatomical structures [4–11,15]. A systematic analysis
of MRI ﬁndings before EBRT and at the time of BT with the applica-
tor in place, provided information helpful to reduce uncertainties
regarding the deﬁnition of GTV, CTVs and patho-anatomical struc-
tures [15]. The parametrial space, as the region of potential tumour
spread, was deﬁned on axial T2-weighted MR images based on vis-
ible radiological criteria [15]. An additional evaluation with sys-
tematic analysis of tumour spread and regression on MRI enabled
the recognition of different types of parametrial spread and regres-
sion and provided a thorough description of extent, quality and
topography of tumour remnants [69]. Based on these two system-
atic evaluations, it appears feasible to accurately deﬁne the target
within the frame of modern adaptive BT on T2-weighted axial MR
images using the adaptive target approach, which was described in
the ﬁrst part of the GYN GEC-ESTRO recommendations [1,15,69].
The information provided with MRI is also valuable for the devel-
opment of novel combined intracavitary and interstitial BT appli-
cators [39,40].
Image quality and image characteristics depend on multiple
parameters which principally vary between MRI scanners. On T2-
weighted MR images, tumour signal intensity decreases with
increasing ﬁeld strength (Fig. 3a and b). It is therefore not only sug-
gested to perform ‘‘Pre-RT MRI examination’’ and ‘‘BT MRI examina-
tion’’ with MRI scanners with similar ﬁeld strength, but to perform
these scans preferably using the same MRI scanner. Uniformity in
image contrast and quality enables direct comparison between
these MRI scans, with assessment of tumour extension and growth
pattern at the time of diagnosis and at the time of BT, as well as
assessment of quantitative and qualitative tumour regression
[4,5,7,10,11,21,66,69] (Fig. 2).
Imaging based on 1.5 T magnets is currently considered as the
standard for diagnostic body imaging. Imaging with open low ﬁeld
MRI scanners has improved over the years, but closed MRI scan-
ners with higher magnetic ﬁeld strength continue to provide supe-
rior images. Scanners with 3 T are increasingly utilised in the
radiology community. With higher ﬁeld strength the signal-to-
noise ratio decreases and the voxel volume can be reduced [70].
However, image distortion, motion artefacts as well as susceptibil-Fig. 3. Differences resulting due to different magnet ﬁeld strength: comparison between
ﬁeld MR scanner (0.2 T (b)). Prior to imaging intravaginal contrast (ultrasound gel) was i
tumour extension. The impact of magnet ﬁeld strength on signal intensity of tumour and
intermediate-to-high signal intensity and the low-ﬁeld images of the same patient withity artefacts increase with increasing ﬁeld strength [57], and fur-
ther improvements are needed to gain the full beneﬁt of the
improved signal-to-noise ratio at 3 T. Higher magnetic ﬁelds, like
7 T and 8 T have been installed only in a few research centres as
they present some technical challenges, e.g. the safety limits can
be exceeded due to higher gradient amplitudes and radiofrequency
power deposition [70,71].
In summary, it is not clear whether imaging with increasing
ﬁeld strength and improvement of image quality can be translated
into increased precision for target delineation for cervical cancer
BT.
The present recommendations for MR imaging for 3D image-
based cervical cancer BT are therefore mainly based on the existing
experience with 0.2 T and 1.5 T machines.
MRI scanners with closed magnet conﬁguration and 1.5 T ﬁeld
strength are used in the majority of institutions [13,18,20,59,65–
67,72]. Both 60 cm and 70 cm openings are suitable to offer sufﬁ-
cient space for patients who are not obese. Whether images ob-
tained with 3 T MRI scanners are appropriate for the deﬁnition of
tumour and BT targets, has to be validated in the future.
Low ﬁeld 0.2–0.5 T open MRI scanners offer improved patient
accessibility and represent the only acceptable option for the
claustrophobic, overweight or obese patient [25,26]. The use of
these scanners for ‘‘Pre-RT MRI examination’’ and ‘‘BT MRI examina-
tion’’ has been described in the literature [15,19,24,67,73,74]. How-
ever, low ﬁeld magnet strength is associated with longer scanning
times [73]. BT experience with more recent open-conﬁguration
high ﬁeld (1–1.5 T) MR scanners has not been reported so far.
In case of complex BT implants (combined intracervical/inter-
stitial implants), low ﬁeld open MRI scanners enable a ‘‘step by
step’’ interventional procedure, which can be performed in the
MRI suite [39]. To date, ‘‘real-time’’ image-guided placement of
MRI-compatible material (intrauterine and intravaginal applicator,
needles, etc.), under the direct guidance of MRI, has not been
implemented, neither by open nor by closed magnet conﬁgura-
tions. This may be due to the lack of ‘‘real-time’’ MR imaging algo-
rithms but may also be associated with hardware related patient
access problems. Nevertheless, in the future development of dedi-
cated MR imaging algorithms combined with high-ﬁeld open bore
magnet technology may provide solutions for such direct guidance
procedures.
Patient preparation and contrast application for MR image
acquisition has to be adapted to the needs of 3D image-based BT
[5,13,15,18–21,65–68].T2w sagittal MR images obtained with a high-ﬁeld MR scanner (1.5 T (a)) and a low-
njected in order to distend the vaginal walls and to improve visualisation of vaginal
intravaginal contrast is signiﬁcant. The high ﬁeld MR images depict the tumour with
high signal intensity.
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most patients. Nevertheless, assessment of initial tumour growth
pattern and extension seems to be also accurate with MRI, after
application of vaginal contrast, since distension of the vaginal walls
improves visualisation of the vaginal walls and lower parts of the
cervix [15,37,38] (Fig. 2). It can be hypothesised, that the contrast
induced vaginal wall distension makes ‘‘Pre-RT MRI examination’’
more comparable to the subsequent ‘‘BT MRI examination’’ with
applicator and packing induced vaginal wall distension [5] (Fig. 2).
Intravenous or intramuscular drug administration in combina-
tion with bowel preparation and an anterior pre-saturation band
improves image quality for both ‘‘Pre-RT MRI examination’’ and
‘‘BT MRI examination’’ due to reduction of bowel motion artefacts
(Fig. 1a and b).
Reproducible bladder ﬁlling for the duration of ‘‘BTMRI examina-
tion’’ acquisition and the duration of the entire treatment and the
planning procedure can be achieved with dedicated protocols
[19,20]. It may be an open urinary catheter or a limited amount of
ﬂuid (e.g. 50 cm2) ﬁlled into the emptied bladder. The aim is tomin-
imise dosimetric and inter-/intra-fraction uncertainties [14,75].
Use of commercially availableMRI-compatible applicators, vagi-
nal packing (e.g. impregnatedwith contrast agents or dry) and foley
catheters (ﬁlled with some contrast media) have been reported as a
feasible way of providing appropriate visibility of relevant struc-
tures during BT [15] (Fig. 2). Intravaginal gauze packing impreg-
nated with diluted Gadolinium and dry gauzes ﬁx the applicator
and displays low-signal intensity, in contrast to the high signal
intensity of tumour for 0.2 T machines [5] and 1.5 T machines,
respectively. Resin-made hollow vaginal mould applicators display
homogeneous peripheral low-signal intensity and represent an-
other option [67,76]. In future, various different solutionswill likely
be developed for appropriate visibility of the application related
‘‘instrumentarium’’ within various clinical and application settings.
Axial, sagittal and coronal oriented T2-weighted images are
among others, the basic sequences for the evaluation of cervical
cancer in diagnostic radiology, and should serve as the basis for
‘‘Pre-RT MRI examination’’ and ‘‘BT MRI examination’’ performed
for the purpose of 3D image-based BT of cervical cancer. Only lim-
ited data about the impact of MR image orientation on contouring
for 3D image-based BT of cervical cancer are available at present. In
an investigation estimating the agreement between High Risk
(HR)-CTV outlines delineated by two observers on transverse and
para-transverse MR images, interobserver and interplanar confor-
mity indices were high, while interobserver variation and interpla-
nar topographic variation of dose volume histogram (DVH)
parameters were not signiﬁcant [21]. However, contouring seemed
to be signiﬁcantly easier in the para-transversal planes. Current
recommendations therefore suggest to use (para)-images orien-
tated parallel and orthogonal to the applicator (sources) axis to ob-
tain a ‘‘BT orientated view’’ (BOV) [21,23].
It has been demonstrated, that para-axial and para-coronal T2-
weighted MR images help to reduce potential misinterpretation
due to partial volume effects. If used for diagnostic purposes, they
improve the depiction of tumour in the parametria, vaginal fornices,
and the lowerparts of the cervix [47].On ‘‘BTMRI examination’’, these
sequences support assessment of GTV, grey zones and CTVs and
facilitate target contouring [15,21]. Para-axial and para-coronal
T2-weighted MR images should not only be performed at time of
BT, when applicator-oriented, but also at ‘‘Pre-RT MRI examination’’.
If MRI for staging also serves as ‘‘Pre-RTMRI examination’’, these two
additional image sequences should be obtained.
If 3D sequences can be improved to provide better contrast
properties for discrimination of cervix and grey zones, a single
acquisition of a 3D T2w high resolution volume data set may serve
as an alternative to the 2D multi-planar T2w imaging). There is
currently some debate whether the 3D isotropic MRI improvesthe diagnostic potential of MRI in pelvic imaging [51–54]. Never-
theless, the contrast generating mechanism during the long spin-
echo readout trains, currently represents the major limitation of
3D MRI. Currently, fusion of the 3D isotropic sequence and the
para-axial T2 weighted sequence represents a good solution to
combine the 3D free formatting with good T2 contrast, in order
to support contouring at the time of BT. The imaging time can be
shortened and an additional DICOM viewer may not be necessary
during delineation, reducing the infrastructural requirements of
the brachytherapy department [22]. Furthermore, imaging with
small slice thickness or the use of 3D high-resolution isotropic
MRI allows for a more accurate and convenient applicator recon-
struction (see also ‘‘Imaging and applicator reconstruction’’) and
has been recommended by the GYN GEC-ESTRO working group [2].
T1-weighted images are complementary to T2-weighted MR
images, and are mostly used for staging purposes for lymph node
evaluation, or, if contrast-enhanced, for tumour evaluation, partic-
ularly if the tumour is not well seen on T2-weighted images.
‘‘Pre-RT MRI examination’’ and ‘‘BT MRI examination’’ should be
accessible in a standardised DICOM format in order to enable im-
age reading on a diagnostic imaging workstation, which should
be placed next to the treatment planning system. Requirements
for the imaging workstation are: multiplanar imaging capability
simultaneous visualisation of multiple planes, reference lines,
scroll capacity and localisation tools, which enable direct compar-
ison of ‘‘Pre-RT MRI examination’’ and ‘‘BT MRI examination’’.
It iswell known that there are signiﬁcant intra- and inter-tumour
variations which are relevant for the response to radiation. Investi-
gation of clinical parameters together with functional imaging
may provide additional biological tools in the future for assessment
of tumour characteristics. Intra-tumour hypoxia in cervical cancer
has proven to predict poor local control and survival [77,78]. Radio
resistance of hypoxic cells may play a crucial role and there is cur-
rently a wide interest in integrating biological information in RT
treatment planning with the aim of targeting radiation resistant re-
gions by creating a heterogeneous dose pattern – the concept has
been designated ‘‘dose painting’’ [79,80]. New possibilities in func-
tional MRI may have potential to supply more information on tu-
mour topography and intra-tumour heterogeneity. Diffusion of
water molecules can be measured with DWI MRI. Tissue with high
density of cells – like tumour tissue – limits the diffusion of water
molecules, and visualisation of diffusionmay have potential to sup-
ply additional information about the extent of the tumour target on
MR images [81,82]. Intra-tumour perfusion and vascularisation can
be visualised by dynamic contrast enhanced (DCE) MRI. The inten-
sity distribution in DCEMRI has shown to correlatewith local recur-
rences, which has generated the hypothesis that signal intensity in
DCE MRI correlates with hypoxia [83,84].
Geometric stability is not a real concern for diagnostic MR
imaging of the pelvis, but stable geometry is crucial for RT plan-
ning. New achievements in MRI technology like novel pulse se-
quences (e.g. DWI) and the introduction of high ﬁeld magnets
(e.g. 3 T) might produce geometric instabilities which can be unac-
ceptable for RT planning [27].
Finally, BT applicator material, increasing magnet ﬁeld strength
and certain pulse sequences are all factors which might introduce
image artefacts inside and in the vicinity of the tumour. The
amount of these artefacts varies. However, for most potential com-
binations of scanners, sequences and BT equipment it is feasible to
develop dedicated imaging protocols in order to obtain geometric
stabilities which are acceptable for BT dose planning.
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